Radiolabeled Thapsigargin Analogs Incorporated into Protease Activated Prodrugs

Case ID:
C10682

Various embodiments of this invention relate generally to targeted activation and delivery of therapeutic drugs to cells that produce prostate specific membrane antigen (PSMA), prostate specific antigen (PSA) or human glandular kallikrein 2 (hK2). Various embodiments relate more specifically to PSA, hK2 or PSMA-specific peptide prodrugs that become activated to yield therapeutic drugs. Further aspects of various embodiments of the present invention also relate to methods and compositions for treating or preventing cancers and methods and compositions for detecting and/or imaging cancers. More particularly, the invention relates to methods and compositions of imaging subjects using PSA, hK2 or PSMA-specific peptide prodrugs.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER PCT: Patent Cooperation Treaty United States 13/257,131 8,772,226 11/29/2011 7/8/2014 3/17/2030 Granted
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Mohit Ganguly
mgangul1@jh.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum